Bulletin
Investor Alert

New York Markets Close in:

Verve Therapeutics Inc.

NAS: VERV

GO
/marketstate/country/us

Market open

 --Real time quotes

Jan 25, 2022, 2:20 p.m.

/zigman2/quotes/227446048/composite

$

31.19

Change

-0.64 -2.01%

Volume

Volume 379,101

Real time quotes

/zigman2/quotes/227446048/composite

Previous close

$ 31.83

$ 31.19

Change

-0.64 -2.01%

Day low

Day high

$29.78

$32.23

Open

52 week low

52 week high

$29.28

$78.00

Open

Company Description

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providi...

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Valuation

Enterprise Value to EBITDA

-40.37

Efficiency

Liquidity

Current Ratio

10.11

Quick Ratio

10.11

Cash Ratio

9.86

Profitability

Return on Assets

-91.35

Return on Total Capital

-105.87

Return on Invested Capital

-119.10

Capital Structure

Total Debt to Total Capital

204.34

Total Debt to Total Assets

159.62

Long-Term Debt to Total Capital

204.34

Officers and Executives

Name Age Officer Since Title
Dr. Sekar Kathiresan 48 2018 Chief Executive Officer
Mr. Andrew D. Ashe 53 2018 President & Chief Operating Officer
Ms. Allison Dorval 44 2021 Chief Financial & Accounting Officer
Ms. Margaret Beaudoin 51 2020 Senior Director-Finance
Dr. Andrew Bellinger - 2019 Chief Scientific Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/04/2022 Sekar Kathiresan
Chief Executive Officer; Director
1,870   Disposition at $39.9 per share. 74,613
01/04/2022 Sekar Kathiresan
Chief Executive Officer; Director
1,870   Derivative/Non-derivative trans. at $1.39 per share. 2,599
12/28/2021 Sekar Kathiresan
Chief Executive Officer; Director
6,693   Disposition at $39.9 per share. 267,050
12/28/2021 Sekar Kathiresan
Chief Executive Officer; Director
6,693   Derivative/Non-derivative trans. at $1.39 per share. 9,303
12/27/2021 Sekar Kathiresan
Chief Executive Officer; Director
770   Disposition at $42.21 per share. 32,501
12/27/2021 Sekar Kathiresan
Chief Executive Officer; Director
4,787   Disposition at $41.24 per share. 197,415
12/27/2021 Sekar Kathiresan
Chief Executive Officer; Director
36,443   Disposition at $40.02 per share. 1,458,448
12/27/2021 Sekar Kathiresan
Chief Executive Officer; Director
42,000   Derivative/Non-derivative trans. at $1.39 per share. 58,380
12/23/2021 Sekar Kathiresan
Chief Executive Officer; Director
57,000   Disposition at $39.9 per share. 2,274,300
12/23/2021 Sekar Kathiresan
Chief Executive Officer; Director
57,000   Derivative/Non-derivative trans. at $1.39 per share. 79,230
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
3,269   Disposition at $39.78 per share. 130,040
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
31,139   Disposition at $39.06 per share. 1,216,289
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
16,718   Disposition at $38.31 per share. 640,466
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
5,874   Disposition at $37.38 per share. 219,570
12/22/2021 Andrew Bellinger
Chief Scientific Officer
4,871   Disposition at $39.37 per share. 191,771
12/22/2021 Andrew Bellinger
Chief Scientific Officer
8,161   Disposition at $38.6 per share. 315,014
12/22/2021 Andrew Bellinger
Chief Scientific Officer
1,968   Disposition at $37.42 per share. 73,642
12/22/2021 Sekar Kathiresan
Chief Executive Officer; Director
57,000   Derivative/Non-derivative trans. at $1.39 per share. 79,230
12/22/2021 Andrew Bellinger
Chief Scientific Officer
15,000   Derivative/Non-derivative trans. at $1.48 per share. 22,200
12/02/2021 Burt A. Adelman
Director
4,700   Acquisition at $31.34 per share. 147,298
12/02/2021 Andrew D. Ashe
See Remarks
4,000   Acquisition at $32.1 per share. 128,400
06/21/2021 GV Management Co. LLC
6,320,905   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
443,265   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
4,029,244   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
443,265   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
4,029,244   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 GV Management Co. LLC
6,320,905   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Casdin Capital LLC
310,285   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Casdin Capital LLC
1,007,311   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Casdin Capital LLC
620,571   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Redmile Group LLC
886,530   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 ARCH Venture Partners LLC
1,254,405   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 ARCH Venture Partners LLC
1,254,404   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Wellington Management Co. LLP
1,152,490   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Wellington Management Co. LLP
1,343,081   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Rock Springs Capital Management LP
152,926   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Rock Springs Capital Management LP
556,298   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Impresa Management LLC
902,986   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Impresa Management LLC
134,308   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Logos Global Management LP
443,265   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Beam Therapeutics, Inc.
270,895   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Cormorant Asset Management LP
709,224   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Novo Holdings A/S (Investment Company)
443,265   Derivative/Non-derivative trans. at $0 per share. 0
06/21/2021 Casdin Capital LLC
1,100,000   Acquisition at $19 per share. 20,900,000
06/21/2021 Redmile Group LLC
1,050,000   Acquisition at $19 per share. 19,950,000
06/21/2021 Rock Springs Capital Management LP
370,000   Acquisition at $19 per share. 7,030,000
06/21/2021 Logos Global Management LP
370,000   Acquisition at $19 per share. 7,030,000
06/21/2021 Sekar Kathiresan
Chief Executive Officer; Director
2,500   Acquisition at $19 per share. 47,500
06/21/2021 Andrew Bellinger
Chief Scientific Officer
5,000   Acquisition at $19 per share. 95,000
06/21/2021 Margaret Beaudoin
Vice President, Finance
1,000   Acquisition at $19 per share. 19,000
06/21/2021 Cormorant Asset Management LP
275,000   Acquisition at $19 per share. 5,225,000
06/21/2021 Novo Holdings A/S (Investment Company)
350,000   Acquisition at $19 per share. 6,650,000
06/21/2021 The Broad Institute, Inc.
387,830   0
/news/latest/company/us/verv

MarketWatch News on VERV

  1. Verve Therapeutics reiterated as hold with $58 stock price target at Stifel

    6:59 a.m. Dec. 23, 2021

    - Ciara Linnane

  2. Gene Editor Verve Unveils Second Way to Lower Cholesterol

    4:19 a.m. Nov. 12, 2021

    - Barron's Online

  3. Beam Gets FDA Nod for First Gene-Editing Trial

    8:10 a.m. Nov. 9, 2021

    - Barron's Online

  4. Gene Therapy Is a Huge Opportunity. It Pays to be Patient.

    8:46 p.m. Nov. 5, 2021

    - Barron's Online

  5. Verve Therapeutics started at hold with $58 stock price target at Stifel Nicolaus

    7:00 a.m. Sept. 24, 2021

    - Tomi Kilgore

  6. Verve started at neutral with $50 stock price target at J.P. Morgan

    6:20 a.m. July 12, 2021

    - Tomi Kilgore

  7. Verve Therapeutics shares soar 68% in trading debut

    11:47 a.m. June 17, 2021

    - Ciara Linnane

/news/nonmarketwatch/company/us/verv

Other News on VERV

  1. Tracking Baker Brothers Portfolio - Q3 2021 Update

    10:32 p.m. Jan. 4, 2022

    - Seeking Alpha

  2. 3 Synthetic Biology Stocks in Focus With Strong Potential

    9:34 a.m. Dec. 24, 2021

    - Zacks.com

  3. Verve Therapeutics picks experienced financial executive as CFO

    8:46 a.m. Nov. 29, 2021

    - Seeking Alpha

  4. 10-Q: VERVE THERAPEUTICS, INC.

    7:06 a.m. Nov. 10, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  5. Why Verve Therapeutics Is Up More Than 16% This Week

    7:49 p.m. Oct. 28, 2021

    - Motley Fool

  6. 2 Gene-Editing Stocks to Have on Your Radar Right Now

    8:01 a.m. Oct. 17, 2021

    - Motley Fool

  7. Tracking Baker Brothers Portfolio - Q2 2021 Update

    11:54 p.m. Oct. 4, 2021

    - Seeking Alpha

  8. Meet members of the 2021 IPO class: Biotechs - 1

    8:57 a.m. Sept. 28, 2021

    - Seeking Alpha

  9. Russell 3000 adds IPO to index

    9:34 a.m. Sept. 17, 2021

    - Seeking Alpha

  10. 10-Q/A: VERVE THERAPEUTICS, INC.

    7:06 a.m. Aug. 16, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  11. 10-Q: VERVE THERAPEUTICS, INC.

    7:55 a.m. Aug. 12, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  12. WHO urges fair access to gene-editing technologies

    10:51 a.m. July 12, 2021

    - Seeking Alpha

  13. Loading more headlines...

At a Glance

Verve Therapeutics, Inc.

500 Technology Square

Suite 901

Cambridge, Massachusetts 02139

Phone

1 6176030070

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

N/A

Net Income

$-45.70M

Employees

-

/news/pressrelease/company/us/verv

Press Releases on VERV

  1. Verve Therapeutics Announces Pricing of Initial Public Offering

    8:24 p.m. June 16, 2021

    - BusinessWire - BZX

Trending Tickers
  • /zigman2/quotes/207505872/composite DISH+1.05%
  • /zigman2/quotes/204151124/composite CURE-1.23%
  • /zigman2/quotes/214908404/composite GFL+1.15%
  • /zigman2/quotes/204236046/composite DUST+1.32%
  • /zigman2/quotes/200683073/composite FRC+0.90%
X
Powered by StockTwits
Link to MarketWatch's Slice.